Elder Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Schering AG
Angeliq approved in the U.S. for treatment of menopausal symptoms
October 26th, 2005
Schering AG, Germany (SCH, SHR) announced that the U.S. Food and Drug Administration (FDA) has approved Angeliq to treat moderate-to-severe menopausal symptoms. Angeliq will be available in the U.S. by prescription in a preparation containing 0.5 mg drospirenone and 1 mg estradiol. Angeliq is different from other available HRT in that it contains the anti-aldosterone progestin drospirenone. Anti-aldosterone activity has been shown to counter the excess water and sodium retention sometimes caused by estrogen. In addition, Angeliq contains estradiol, the same estrogen produced by a woman's body prior to menopause. "We have seen great success with our...
Source: Elder Law Weekly (2005-10-26)
|
